据业绩快报，艾迪药业报告期内实现营收7.21亿元，同比增长72.49%，亏损规模由2024年的1.41亿元收 窄至2025年的1973.37万元，亏损幅度同比下降86.02%。值得注意的是，已经连续多年亏损的艾迪药业 在2025年实现营业利润扭亏，达4774.60万元。 艾迪药业主要业务聚焦于抗HIV及人源蛋白领域两条赛道。在抗HIV领域，公司拥有艾诺米替、艾诺韦 林等创新药。其中，艾诺韦林片为全新结构的非核苷类逆转录酶抑制剂，于2021年6月获批上市，用于 治疗HIV-1感染初治患者，该药为第二款国产自主研发的抗艾滋病1类新药；艾诺米替片系在艾诺韦林 的基础上，加入两个核苷类逆转录酶抑制剂（NRTIs）——富马酸替诺福韦二吡呋酯和拉米夫定所组成 的复方制剂，于2022年12月获批国内上市，2024年9月新增适应症上市申请获得批准。该药也是国内首 款具有自主知识产权的抗HIV口服1类新药。在中国艾滋病诊疗指南（2024版）中，两款药品作为复方 单片制剂，成为成人及青少年初始抗逆转录病毒疗法方案，获A1级推荐。截至目前，两款药物均已进 入国家医保目录。 2月25日，艾迪药业发布2025年业绩快报，得益于抗HIV ...

Core Viewpoint - Jiangsu Aidi Pharmaceutical (688488.SH) announced a plan to acquire minority shareholder equity in its subsidiary, Nanjing Nanda Pharmaceutical, which will increase its direct shareholding from 51.13% to 73.36% [1][3] Group 1: Acquisition Details - Aidi Pharmaceutical plans to raise up to 185 million yuan through a simplified procedure to fund the acquisition, with 130 million yuan allocated for acquiring 22.23% of Nanda Pharmaceutical's equity and 55 million yuan for working capital [1] - The acquisition is expected to enhance Aidi's control over Nanda Pharmaceutical and optimize financial performance, maximizing synergies between the two companies [4][10] Group 2: Market Potential - The demand for stroke treatment is anticipated to surge, with acute ischemic stroke cases in China projected to rise from 4.1 million in 2023 to 4.9 million by 2027 [4] - The market for neuroprotective drugs in China is expected to grow from 11.5 billion yuan in 2024 to 16.9 billion yuan by 2030, and further to 26.2 billion yuan by 2035 [4] Group 3: Product Pipeline - Aidi's new drugs, AD108 injection and ADB116 injection, are positioned to become significant profit growth drivers, targeting acute ischemic stroke treatment [4] - Aidi's HIV drug, Enomirac, has shown strong sales potential, with revenue from HIV drugs reaching 211 million yuan in the first three quarters of 2025, a 57.12% increase year-on-year [6][7] Group 4: International Expansion - Aidi Pharmaceutical is accelerating its international market expansion, with its HIV drug Enomirac approved for sale in Zanzibar, marking a significant milestone for Chinese-developed HIV drugs in Africa [9] - The company is also advancing its pipeline of innovative drugs, including a new HIV integrase inhibitor and long-acting pre-exposure prophylaxis drugs, which are in various stages of clinical trials [10]

Group 1 - The core point of the article is that Jiangsu Aidi Pharmaceutical Group announced a plan to raise up to 185 million yuan through a simplified procedure for issuing A-shares, primarily to acquire a 22.23% stake in its subsidiary Nanjing Nanda Pharmaceutical Co., Ltd. for approximately 130.06 million yuan and to supplement working capital with 55 million yuan [1][2] - The chairman of Aidi Pharmaceutical, Fu Helian, stated that this move is a significant step towards focusing on the core business and enhancing competitive strength, aimed at long-term strategic development [1] - Nanda Pharmaceutical specializes in thrombolytic drugs and low molecular weight heparin raw materials, being one of the few companies in China that holds production licenses for both raw materials and injectable formulations [1] Group 2 - Aidi Pharmaceutical previously acquired a 19.96% stake in Nanda Pharmaceutical in July 2022 and plans to further purchase an additional 31.16% stake in 2024, thereby gaining control over Nanda Pharmaceutical [2] - The acquisition of the additional 22.23% stake will enhance Aidi Pharmaceutical's control over Nanda Pharmaceutical, promoting strategic management upgrades and improving financial performance [2] - Aidi Pharmaceutical has maintained rapid growth in the HIV treatment sector for three consecutive years and is focused on advancing its core research pipeline and establishing a comprehensive commercialization system for new HIV drugs [2]

Group 1 - The company, Jiangsu Aidi Pharmaceutical Group Co., Ltd., plans to raise up to 185 million yuan through a simplified procedure to issue A-shares, primarily to acquire a 22.23% stake in its subsidiary, Nanjing Nanda Pharmaceutical Co., Ltd., for approximately 130 million yuan, and to supplement working capital with 55 million yuan [1] - Nanda Pharmaceutical specializes in thrombolytic drugs and low molecular weight heparin raw materials, making it one of the few integrated manufacturers in China holding production approvals for both raw materials and injectable formulations [2] - The acquisition of Nanda Pharmaceutical is expected to enhance the company's control over it, optimize financial performance, and maximize synergies, thereby strengthening its competitive position in the human protein sector [3] Group 2 - The stroke incidence in China is rising, with acute ischemic stroke cases projected to increase from 4.1 million in 2023 to 4.9 million by 2027, highlighting a significant unmet clinical need for effective stroke treatments [3] - The market for neuroprotective drugs in China is expected to grow from 11.5 billion yuan in 2024 to 16.9 billion yuan by 2030, and further to 26.2 billion yuan by 2035, indicating a strong demand for innovative stroke medications [3] - Aidi Pharmaceutical has maintained rapid growth in the HIV sector for three consecutive years, with the market for anti-HIV drugs in China estimated at 7 billion yuan in 2023, projected to exceed 11 billion yuan by 2027 [4] Group 3 - The company is advancing its core HIV pipeline and aims to establish a comprehensive commercialization system for new HIV drugs, addressing the significant challenge posed by the large population of HIV-infected individuals in China [4] - Aidi Pharmaceutical has made significant progress in its HIV drug pipeline, with new drugs like ACC017 and ADC118 entering clinical trials, and is also developing long-acting pre-exposure prophylaxis drugs [5] - The 55 million yuan raised will be used to support operational funding and accelerate the development of core research projects, ensuring the efficient rollout of a diverse and comprehensive HIV drug commercialization strategy [5]